Last Updated: November 16, 2026

Polatuzumab vedotin-piiq - Biologic Drug Details

« Back to Dashboard


Summary for polatuzumab vedotin-piiq
Tradenames:1
High Confidence Patents:0
Applicants:1
BLAs:1
Suppliers: see list1
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for polatuzumab vedotin-piiq Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for polatuzumab vedotin-piiq Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for polatuzumab vedotin-piiq Derived from Patent Text Search

No patents found based on company disclosures

Polatuzumab Vedotin-Piiq Market Dynamics, Sales Growth, Patent Protection, and Competitive Outlook

Last updated: October 22, 2026

Polatuzumab vedotin-piiq, marketed as Polivy by Roche and Genentech, has moved from a salvage therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) into a first-line treatment platform. Roche reported approximately CHF 1.0 billion in Polivy sales in 2023, following rapid growth after the drug entered untreated DLBCL. The main commercial opportunity is first-line substitution for part of the R-CHOP market. The main risks are competition from CAR-T therapies, bispecific antibodies, other antibody-drug conjugates, treatment toxicity, and eventual biosimilar development.

What is polatuzumab vedotin-piiq and how is Polivy used?

Polatuzumab vedotin-piiq is an antibody-drug conjugate targeting CD79b, a B-cell receptor component expressed on most B-cell malignancies. The antibody is linked to monomethyl auristatin E, or MMAE, through a protease-cleavable linker. After binding to CD79b, the conjugate is internalized and releases MMAE, disrupting microtubules and causing cell death.

The FDA approved Polivy in June 2019 under the accelerated approval pathway for adults with relapsed or refractory DLBCL after at least two prior therapies. The initial regimen combined Polivy with bendamustine and rituximab for six cycles.

In April 2023, the FDA granted regular approval for untreated DLBCL or high-grade B-cell lymphoma in adults with an International Prognostic Index score of at least 2. The approved first-line regimen combines Polivy with rituximab, cyclophosphamide, doxorubicin and prednisone, commonly known as Pola-R-CHP. The approval was based primarily on the POLARIX Phase 3 trial, which showed improved progression-free survival compared with R-CHOP, although the overall-survival result was not statistically significant at the initial analysis. [1][2]

Key FDA milestones

Date Regulatory event Commercial effect
June 2019 Accelerated approval for relapsed or refractory DLBCL after at least two prior therapies Established Polivy in a limited salvage market
December 2021 FDA conversion of the original indication to regular approval after confirmatory data Reduced regulatory uncertainty for the original use
April 19, 2023 Approval with R-CHP for previously untreated DLBCL or high-grade B-cell lymphoma in adults with IPI of at least 2 Expanded Polivy into the substantially larger first-line market
2023 onward Broader guideline and payer adoption of Pola-R-CHP Shifted revenue mix toward frontline treatment

How has Polivy revenue developed?

Polivy revenue has grown sharply since the 2023 first-line approval. Roche reported sales in Swiss francs, and year-to-year comparisons are affected by currency movements, launch timing and geographic reimbursement.

Fiscal year Approximate Roche Polivy sales Commercial interpretation
2021 CHF 0.4 billion Primarily relapsed or refractory use
2022 CHF 0.6-0.7 billion Continued salvage-market penetration and pre-launch preparation
2023 Approximately CHF 1.0 billion First-line launch materially expanded the market
2024 Continued growth reported by Roche Broader adoption of Pola-R-CHP offset maturity in the original indication

Roche’s 2023 annual report reported Polivy sales of approximately CHF 1.0 billion, with growth driven by the first-line DLBCL indication. [3] The product is now one of Roche’s important growth assets in hematology, although it remains smaller than major products such as Ocrevus, Hemlibra and Vabysmo.

The revenue trajectory has three phases:

  1. The 2019-2021 period was limited by the size of the relapsed DLBCL population and the requirement for multiple prior lines of treatment.
  2. The 2022 period reflected preparation for the first-line launch and expanding use in eligible relapsed patients.
  3. The 2023 onward period reflects access to the larger newly diagnosed DLBCL population.

The first-line indication materially changes the product’s revenue ceiling. DLBCL is one of the most common aggressive non-Hodgkin lymphomas, and R-CHOP has been the standard first-line regimen for decades. Even partial conversion to Pola-R-CHP creates a large commercial opportunity because treatment begins at diagnosis rather than after multiple treatment failures.

What is the market size for Polivy?

The addressable market consists of two distinct segments.

First-line DLBCL

The first-line market is the largest opportunity. Polivy is generally considered for adults with previously untreated DLBCL or high-grade B-cell lymphoma who meet the approved risk criteria. The commercial opportunity depends on:

  • Number of new DLBCL diagnoses
  • Proportion with IPI scores of at least 2
  • Physician preference for Pola-R-CHP over R-CHOP
  • Payer reimbursement
  • Hospital treatment protocols
  • Patient ability to tolerate an intensified antibody-drug conjugate regimen

Polivy does not need to replace all R-CHOP use to generate significant revenue. A minority-to-majority share of eligible first-line patients could support sustained multibillion-franc potential, depending on price, dosing duration and geographic uptake.

Relapsed or refractory DLBCL

The original market remains commercially relevant but is more competitive. Patients may receive Polivy-based therapy, CAR-T treatment, bispecific antibodies, tafasitamab plus lenalidomide, loncastuximab tesirine or other salvage approaches.

The relapse market has higher clinical urgency but fewer patients. It also has more treatment sequencing complexity. A patient who is eligible for second-line CAR-T may not receive Polivy-based salvage therapy, while older or medically frail patients may be more likely to receive an antibody-drug conjugate or bispecific antibody.

How does Polivy compare with competing DLBCL therapies?

Therapy Company or companies Main competitive position Effect on Polivy
R-CHOP Multiple manufacturers Established first-line standard Main substitution target for Pola-R-CHP
Pola-R-CHP Roche/Genentech First-line DLBCL regimen Drives market expansion
CAR-T therapies Novartis, Gilead/Kite, Bristol Myers Squibb and others High-value treatment for selected relapsed or refractory patients Limits salvage-market growth
Epcoritamab AbbVie/Genmab Subcutaneous bispecific antibody for relapsed or refractory large B-cell lymphoma Competes in later lines
Glofitamab Roche Bispecific antibody for relapsed or refractory DLBCL Creates internal portfolio overlap
Tafasitamab plus lenalidomide Incyte/MorphoSys Relapsed DLBCL option for selected patients Competes with Polivy in non-CAR-T patients
Loncastuximab tesirine ADC Therapeutics CD19-directed antibody-drug conjugate Competes in later-line ADC use
Epcoritamab and glofitamab combinations AbbVie/Genmab and Roche Potentially earlier-line or combination strategies Could change treatment sequencing

Roche has a mixed competitive position. Polivy benefits from Roche’s hematology infrastructure, while Roche’s own glofitamab may compete with Polivy in relapsed disease. This portfolio overlap can allow Roche to retain value across multiple treatment lines, but it can also shift internal sales from one product to another.

What patents protect Polivy?

Polivy is a biologic drug, so its U.S. protection does not follow the same Orange Book structure as a conventional small-molecule drug.

The core protection is likely distributed across several patent families covering:

  • Anti-CD79b antibodies
  • Polatuzumab antibody sequences
  • Antibody-drug conjugates using the antibody
  • Linker-payload chemistry involving vedotin and MMAE
  • Conjugation methods
  • Pharmaceutical compositions
  • Therapeutic use in B-cell malignancies
  • Manufacturing and cell-culture processes

Roche and Genentech control the principal Polivy intellectual-property position. The vedotin ADC platform is associated with technology developed through the Seagen, formerly Seattle Genetics, ADC platform and related licensing and collaboration arrangements. [4]

Is Polivy listed in the Orange Book?

No. The FDA Orange Book is primarily used for approved small-molecule drugs and does not provide the same patent-listing framework for biologics. Polivy is regulated as a biologic and is identified in the FDA Purple Book rather than through a conventional Orange Book patent listing.

The Purple Book identifies licensed biological products, reference products and biosimilar relationships. It does not provide a complete public patent table comparable to the Orange Book. The lack of an Orange Book listing does not mean that Polivy lacks patent protection.

When does Polivy lose regulatory exclusivity?

Polivy received its first U.S. biologics license in 2019. Under the Biologics Price Competition and Innovation Act, a reference biologic generally receives 12 years of reference-product exclusivity from first licensure, subject to statutory interpretation and FDA determinations. On that basis, the principal U.S. regulatory exclusivity period extends into 2031. [5]

Patent protection can extend beyond regulatory exclusivity. The commercial entry date for a biosimilar therefore depends on:

  • Expiration of relevant composition and formulation patents
  • Patent litigation under the BPCIA
  • Any valid patent-term adjustment or patent-term extension
  • Settlement agreements
  • FDA approval timing
  • Manufacturing readiness
  • Whether a biosimilar sponsor seeks interchangeability

The most important practical point is that Polivy’s commercial exposure is unlikely to be determined by a single expiry date. A layered estate covering the antibody, ADC construction, formulation and manufacturing process can delay competition beyond the end of the 12-year reference-product exclusivity period.

Are there Paragraph IV challenges to Polivy?

Traditional Paragraph IV challenges apply to abbreviated new drug applications for small-molecule drugs. They do not apply to Polivy in the same way because Polivy is a biologic.

A competing biologic would generally pursue the biosimilar pathway under the Public Health Service Act. The competitor could engage in the BPCIA patent-information exchange, often called the patent dance, and could face patent litigation under the relevant federal procedures.

There was no widely reported public Polivy biosimilar litigation or settlement comparable to major small-molecule Paragraph IV cases through the available 2024 public record. The absence of a public challenge does not eliminate future biosimilar risk. It indicates that the product’s technical complexity, market size, remaining exclusivity and patent position have not yet produced a visible U.S. biosimilar launch contest.

How strong is the Polivy patent estate?

Polivy has a stronger protection profile than a product covered only by a method-of-use patent because its value is tied to a complex antibody-drug conjugate.

The principal strengths are:

  • The product uses a defined antibody and conjugate architecture.
  • The ADC requires specialized conjugation and analytical control.
  • The active biologic is difficult to reproduce precisely.
  • Manufacturing comparability is more complex than for a small molecule.
  • The first-line indication creates commercial value even if some later-line claims are challenged.
  • The reference product has clinical data supporting use in both relapsed and untreated DLBCL.

The main weaknesses are:

  • A biosimilar sponsor can challenge individual patent claims without reproducing every aspect of Roche’s platform.
  • Some broad ADC or antibody claims may face validity challenges.
  • Method-of-use claims can be narrower than composition claims.
  • Physician adoption can move to competing bispecific antibodies or cellular therapies without requiring a patent challenge.
  • The biologic exclusivity period is finite.

Commercial strength is therefore higher than the legal strength of any single patent. The combination of regulatory data, manufacturing complexity, multiple patent families and Roche’s market access position forms the more durable barrier.

What biosimilar risk exists for Polivy?

Biosimilar risk is low in the near term and rises in the early 2030s. Polivy is more difficult to copy than a standard monoclonal antibody because it combines:

  • A therapeutic antibody
  • A cytotoxic small-molecule payload
  • A cleavable linker
  • A controlled drug-to-antibody ratio
  • A defined conjugation profile
  • Complex potency and impurity testing

A future biosimilar sponsor would need to demonstrate high similarity in structure, function, pharmacokinetics and immunogenicity. The sponsor would also need to manage occupational and manufacturing risks associated with MMAE.

Biosimilar entry could still occur without clinical development matching the full original program. FDA may permit an abbreviated data package if analytical and functional similarity is strong. The likely first impact would be price pressure in hospital channels and competitive tendering, followed by broader erosion if interchangeability or payer substitution develops.

What manufacturing and intellectual-property barriers protect Polivy?

Manufacturing is a meaningful barrier. The process requires production of the antibody, controlled attachment of the linker-payload, purification, characterization and sterile fill-finish. Each stage affects product quality and clinical performance.

Key manufacturing risks for a competitor include:

  • Batch-to-batch variation in drug-to-antibody ratio
  • Aggregation and free-payload impurities
  • Conjugation-site distribution
  • Payload containment
  • Stability during storage and transport
  • Analytical comparability
  • Scale-up of a high-potency cytotoxic product

These barriers can slow entry even after patents expire. They also increase the value of Roche’s established manufacturing network and regulatory history.

What litigation and settlement risks affect Polivy?

No major public U.S. Polivy patent litigation or Paragraph IV settlement was widely reported through 2024. The more probable future legal pathway is BPCIA litigation involving a biosimilar sponsor.

Potential disputes could involve:

  • Antibody sequence claims
  • ADC composition claims
  • Linker-payload claims
  • Conjugation process claims
  • Formulation claims
  • Treatment claims for first-line DLBCL
  • Patent-term calculations
  • Biosimilar notice and launch timing

A settlement could permit entry before the end of the full patent estate while preserving some market exclusivity for Roche. The economic terms would likely depend on the number of viable biosimilar sponsors, the strength of composition claims and the size of Pola-R-CHP sales.

What is the FDA regulatory outlook for Polivy?

The regulatory outlook is favorable for the approved indications. The key regulatory risk is not immediate withdrawal but label expansion, safety management and competitive clinical differentiation.

Important safety considerations include peripheral neuropathy, myelosuppression, infections, infusion-related reactions and tumor lysis syndrome. These risks can affect treatment selection, especially in older patients and those with substantial comorbidity. [1]

The most commercially important regulatory question is whether additional Polivy combinations can increase use without worsening toxicity. Combination studies with other hematology agents could expand treatment sequencing, but they could also increase competition with Roche’s own bispecific products.

What generic launch scenarios exist for Polivy?

Scenario 1: No biosimilar before the early 2030s

Roche retains a high level of pricing and volume control. Revenue continues to grow through first-line adoption, with later-line erosion caused mainly by competing therapies rather than price competition.

Scenario 2: One biosimilar enters after regulatory exclusivity

The first entrant gains access to selected payer and hospital accounts. Roche protects premium positioning through contracting, clinical data and supply reliability. Net price declines are moderate at first.

Scenario 3: Multiple biosimilars enter after patent settlements

Price erosion accelerates. Hospital tenders and payer formularies create pressure across first-line and relapsed settings. Revenue declines become more pronounced, particularly if Pola-R-CHP has limited differentiation over R-CHOP in overall survival.

Scenario 4: Clinical displacement before biosimilar entry

Bispecific antibodies or cellular therapies reduce Polivy use in relapse, while R-CHOP remains strong in first-line patients who are not eligible for Polivy. Roche’s revenue trajectory weakens without any patent loss.

How does Polivy compare with Roche’s other hematology assets?

Polivy has a different commercial profile from Roche’s established hematology products.

Product Area Commercial profile
Polivy DLBCL and large B-cell lymphoma Growth product with first-line expansion and ADC complexity
Gazyva Chronic lymphocytic leukemia and follicular lymphoma Mature anti-CD20 franchise with combination use
Rituxan Multiple B-cell malignancies Large, mature product exposed to biosimilar competition
Venclexta CLL and acute myeloid leukemia Oral targeted therapy with broad combination use
Hemlibra Hemophilia A High-growth specialty product with a different reimbursement model
Glofitamab Relapsed or refractory DLBCL Newer bispecific asset that may compete with or complement Polivy

Polivy gives Roche exposure to frontline DLBCL, while glofitamab provides a later-line bispecific option. The combination allows Roche to participate in multiple treatment stages, but internal substitution is possible.

Key Takeaways

  • Polatuzumab vedotin-piiq is Roche’s CD79b-directed antibody-drug conjugate marketed as Polivy.
  • The April 2023 FDA approval with R-CHP expanded Polivy from a limited salvage product into the first-line DLBCL market.
  • Roche reported approximately CHF 1.0 billion in Polivy sales in 2023.
  • Polivy is a biologic and is not subject to conventional Orange Book Paragraph IV litigation.
  • U.S. reference-product exclusivity generally extends into 2031 based on the 2019 first licensure date.
  • The product’s protection depends on layered antibody, ADC, formulation, use and manufacturing patents rather than a single Orange Book listing.
  • Near-term biosimilar risk is limited by ADC complexity, manufacturing requirements and regulatory barriers.
  • The largest commercial risks are clinical competition from bispecific antibodies and CAR-T therapies, continued R-CHOP use, toxicity and later biosimilar entry.
  • Roche’s own glofitamab creates both a portfolio advantage and a potential source of internal competition.
  • First-line penetration, rather than relapsed-market share, is the main determinant of Polivy’s long-term revenue trajectory.

FAQs

Is Polivy a chemotherapy drug or a biologic?

Polivy is a biologic antibody-drug conjugate. It combines a CD79b-targeting monoclonal antibody with the cytotoxic payload MMAE.

Does Polivy have a biosimilar?

No widely marketed U.S. biosimilar to Polivy was reported through 2024. Future competitors would use the biosimilar pathway rather than a conventional ANDA.

Is polatuzumab vedotin-piiq interchangeable with rituximab?

No. Polivy and rituximab are different biologic products with different targets, structures and FDA approvals. Polivy is used in combination with rituximab-containing regimens.

What is the main clinical alternative to Pola-R-CHP?

R-CHOP remains the principal first-line alternative. In relapsed disease, alternatives include CAR-T therapy, glofitamab, epcoritamab, tafasitamab-based treatment and loncastuximab tesirine.

Who owns Polivy?

Roche and its U.S. subsidiary Genentech commercialize Polivy. The product uses ADC technology associated with the Seagen/Seattle Genetics vedotin platform and related collaboration and licensing arrangements.

References

  1. U.S. Food and Drug Administration. (2023). Polivy prescribing information. https://www.accessdata.fda.gov
  2. Tilly, H., Morschhauser, F., Sehn, L. H., Friedberg, J. W., Trneny, M., Haioun, C., et al. (2022). Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. New England Journal of Medicine, 386(4), 351-363.
  3. Roche. (2024). Annual report 2023. F. Hoffmann-La Roche Ltd.
  4. Seagen Inc. (2020). Annual report and ADC technology disclosures.
  5. U.S. Food and Drug Administration. (2020). Biologics Price Competition and Innovation Act of 2009: Reference product exclusivity. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilar-product-regulatory-review-and-approval-part-iii-reference-product-exclusivity

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.